Status: Finalised
First registered on:
06/06/2017
Last updated on:
28/02/2019
1. Study identification
EU PAS Register NumberEUPAS19445
Official titleA drug utilisation study of Rifaxamin-α 550mg
Study title acronym
Study typeObservational study
Brief description of the studyA drug utilisation study conducted in CPRD GOLD to understand the dosing, the formulation, the indications and the patient demographics associated with rifaximin-α 550mg tablets across the UK following launch in January 2013.
Was this study requested by a regulator?Yes: United Kingdom
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 3 (required)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsCPRD
Department/Research group
Organisation/affiliationClinical Practice Research Datalink
Details of (Primary) lead investigator
Title Ms
Last name Campbell
First name Jennifer
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed16/12/201418/12/2014
Start date of data collection21/04/201506/07/2016
Start date of data analysis
Date of interim report, if expected
Date of final study report09/07/201518/01/2017
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesNorgine Ltd100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Mr
Last name Amlani
First name Bharat
Address line 1Norgine House
Address line 2Widewater Place
Address line 3Moorhall Road
CityUxbridge
PostcodeUB9 6NS
CountryUnited Kingdom
Phone number (incl. country code)44-1895-826622
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Mr
Last name Amlani
First name Bharat
Address line 1Norgine House
Address line 2Widewater Place
Address line 3Moorhall Road
CityUxbridge
PostcodeUB9 6NS
CountryUnited Kingdom
Phone number (incl. country code)44-1895-826622
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Product NameTargaxan
CountryUnited Kingdom
Substance INN(s)RIFAXIMIN
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
Other population
Renal impaired
Hepatic impaired
Immunocompromised
Pregnant women
9. Number of subjects
Estimated total number of subjects400
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
To determine the characteristics of patients in the UK prescribed Rifaxamin 550mg and to gain understanding of the risk associated with use of Rifaxamin 550mg and paediatric use, off-label use and drug-drug interactions
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
The drug utilisation study will characterise the dosing, formulation, the indications and the patient demographics associated with rifaxamin 550mg tablets across the UK following launch in January 2013. Tables of descriptive data (including counts, mean, median, standard deviation and interquartile range) on each patient cohort will be presented.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
